Search
Have you ever wondered about what types of benefits and executive compensation issues you should be thinking about in M&A transactions? This presentation provides an overview of these topics and an issue spotting guide, which will be beneficial for those involved in M&A and for those who otherwise...
Please join us for an upcoming tech M&A workshop, Selling Up Selling Out: Live in Minneapolis, organized by Corum Group at our offices on Wednesday, August 9th. Saul Ewing LLP is sponsoring the half-day conference, where you can hear from former CEOs and market experts as they cover valuations...
Welcome to Saul Ewing’s Public Companies Quarterly Update series. Our intent is to, on a quarterly basis, highlight important legal developments of which we think public companies should be aware. This edition is related to developments during the second quarter of 2023. If you would like to discuss...
On April 5, 2023, Saul Ewing Partner Andy Daly spoke to the Arrowhead Estate Planning Counsel in Duluth, MN on ESOPs and Estate Planning .
Saul Ewing attorneys, Sean O’Neill and Michael Gold , discuss new ESG regulations in connection with the Real Estate industry and Real Estate Investment Trusts (REITs). New regulations from the U.S. Department of Labor and proposed regulations from the Securities & Exchange Commission have created...
Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...
Darius Gambino with Danny Cevallos - on Andy Warhol/Prince SCOTUS Case and Copyright Law in Art Danny Cevallos guest hosts the Michael Smerconish Program where he invites Saul Ewing's Darius Gambino to talk copyright law in art and music. Original air date, 14 October 2022.
Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...